🇺🇸 Physician Assistant National Certifying Examination (PANCE) · subject

Physician Assistant National Certifying Examination (PANCE) Cardiovascular System Syllabus

The Cardiovascular System syllabus for Physician Assistant National Certifying Examination (PANCE) in full: 5 chapters, 22 topics and 29 sub-topics, every one listed below, plus 50 Cardiovascular System flashcards with answers.

5Chapters
22Topics
29Sub-topics
50Flashcards

Cardiovascular System syllabus: all 5 chapters

Expand any chapter to see its topics and sub-topics.

  1. Coronary Heart Disease and Acute Coronary Syndromes

    4 topics
    • Stable angina pectoris
      • Pathophysiology of myocardial oxygen supply-demand mismatch
      • Stress testing and coronary angiography indications
      • Antianginal therapy: beta-blockers, nitrates, calcium channel blockers
    • Unstable angina and NSTEMI
      • Troponin kinetics and serial biomarker interpretation
      • TIMI and GRACE risk stratification
      • Antiplatelet and anticoagulation management
    • ST-elevation myocardial infarction
      • ECG localization of infarct territory
      • Reperfusion: PCI versus fibrinolysis timing
      • Post-MI complications and secondary prevention
    • Coronary risk factor modification
      • Statin intensity and lipid targets
      • Hypertension and diabetes control
  2. Heart Failure and Cardiomyopathies

    4 topics
    • Heart failure with reduced ejection fraction
      • Guideline-directed medical therapy: ARNI, beta-blocker, MRA, SGLT2 inhibitor
      • Device therapy: ICD and CRT indications
    • Heart failure with preserved ejection fraction
    • Acute decompensated heart failure management
      • Diuresis and afterload reduction
      • Cardiogenic shock recognition
    • Dilated, hypertrophic, and restrictive cardiomyopathy
  3. Arrhythmias and Conduction Disorders

    5 topics
    • Atrial fibrillation and flutter
      • Rate versus rhythm control strategies
      • CHA2DS2-VASc and anticoagulation decisions
    • Supraventricular tachycardias
      • AVNRT and AVRT mechanisms
      • Vagal maneuvers and adenosine
    • Ventricular tachycardia and fibrillation
    • Bradyarrhythmias and AV blocks
      • First, second, and third degree heart block
      • Pacemaker indications
    • Long QT and inherited channelopathies
  4. Valvular and Structural Heart Disease

    4 topics
    • Aortic stenosis and regurgitation
      • Murmur characteristics and severity grading
      • Valve replacement timing (SAVR/TAVR)
    • Mitral stenosis and regurgitation
    • Infective endocarditis
      • Duke criteria
      • Prophylaxis indications
    • Rheumatic heart disease
  5. Vascular Disease and Hypertension

    5 topics
    • Essential and secondary hypertension
      • Staging and lifestyle/pharmacologic management
      • Hypertensive urgency versus emergency
    • Aortic aneurysm and dissection
    • Peripheral arterial disease
      • Ankle-brachial index
      • Claudication management
    • Venous thromboembolism and chronic venous insufficiency
    • Lipid disorders and dyslipidemia

Physician Assistant National Certifying Examination (PANCE) Cardiovascular System flashcards — 50 questions with answers

  1. What clinical features define stable angina pectoris?

    Substernal chest pressure/discomfort that is (1) provoked by exertion or emotional stress, (2) relieved within minutes by rest or nitroglycerin, and (3) reproducible/predictable. It reflects fixed coronary stenosis causing demand-supply mismatch without myocyte necrosis (normal troponin).

  2. What is the first-line antianginal and prognostic medication regimen for chronic stable angina?

    Symptom control: beta-blocker first-line (or calcium channel blocker if intolerant), plus sublingual nitroglycerin PRN. Prognosis/secondary prevention: high-intensity statin, antiplatelet (aspirin), and ACE inhibitor/ARB if diabetes, hypertension, CKD, or LV dysfunction.

  3. How are unstable angina (UA) and NSTEMI distinguished from each other?

    Both are non-ST-elevation acute coronary syndromes with ischemic symptoms at rest/crescendo and possible ST depression or T-wave inversion. The difference is biomarkers: NSTEMI has elevated troponin (myocyte necrosis), whereas UA has normal troponin.

  4. What is the initial medical management of UA/NSTEMI?

    Dual antiplatelet therapy (aspirin + P2Y12 inhibitor such as ticagrelor or clopidogrel), anticoagulation (heparin), beta-blocker, high-intensity statin, nitrates for symptoms, and oxygen only if $\text{SpO}_2 < 90\%$. Risk-stratify (TIMI/GRACE) for early invasive angiography.

  5. What ECG criteria define ST-elevation myocardial infarction (STEMI)?

    New ST elevation at the J point in $\geq 2$ contiguous leads: $\geq 1\,\text{mm}$ in limb leads, and in $V_2\text{–}V_3$ $\geq 2\,\text{mm}$ in men ($\geq 2.5\,\text{mm}$ if age $<40$) or $\geq 1.5\,\text{mm}$ in women. New LBBB with ischemic symptoms is treated similarly.

  6. Which coronary artery and infarct territory correspond to ST elevation in leads II, III, and aVF?

    Inferior wall MI, usually from the right coronary artery (RCA). Beware concurrent right ventricular infarction—obtain right-sided leads ($V_4R$) and avoid nitrates/preload-reducers if RV infarct is present.

  7. What is the reperfusion goal time for STEMI with primary PCI versus fibrinolysis?

    Primary PCI is preferred with a door-to-balloon time $\leq 90$ minutes (or $\leq 120$ minutes if transfer needed). If PCI is unavailable within that window, give fibrinolytics within a door-to-needle time $\leq 30$ minutes.

  8. List the standard post-MI discharge medications proven to improve survival.

    Dual antiplatelet therapy (aspirin + P2Y12 inhibitor), high-intensity statin, beta-blocker, and ACE inhibitor/ARB (especially with reduced EF, HTN, DM, or anterior MI). Add aldosterone antagonist if $\text{EF} \leq 40\%$ with HF or diabetes.

  9. What are the major modifiable coronary risk factors?

    Hypertension, dyslipidemia (high LDL/low HDL), diabetes mellitus, cigarette smoking, obesity, physical inactivity, and unhealthy diet. Smoking cessation is the single most cost-effective intervention.

  10. What LDL and lifestyle targets are emphasized in coronary risk factor modification for a patient with established ASCVD?

    High-intensity statin to lower LDL $\geq 50\%$ (goal LDL $< 70\,\text{mg/dL}$, often $<55$ in very high risk); BP target generally $<130/80\,\text{mmHg}$; HbA1c individualized (often $<7\%$); complete smoking cessation; and $\geq 150$ minutes/week of moderate aerobic activity.

  11. Define heart failure with reduced ejection fraction (HFrEF).

    Clinical heart failure syndrome with left ventricular ejection fraction $\leq 40\%$. It is characterized by impaired systolic contractility, eccentric (dilated) LV remodeling, and neurohormonal activation (RAAS and sympathetic).

  12. What are the four pillars of guideline-directed medical therapy for HFrEF?

    (1) ARNI (sacubitril/valsartan) or ACEi/ARB, (2) beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), (3) mineralocorticoid receptor antagonist (spironolactone/eplerenone), and (4) SGLT2 inhibitor (dapagliflozin/empagliflozin). All reduce mortality.

  13. Define heart failure with preserved ejection fraction (HFpEF) and its core pathophysiology.

    Clinical heart failure with $\text{EF} \geq 50\%$. The problem is diastolic dysfunction—a stiff, poorly relaxing LV causing elevated filling pressures with normal contractility. Often associated with hypertension, obesity, diabetes, and aging.

  14. What is the cornerstone treatment for HFpEF?

    Manage volume with diuretics, aggressively control blood pressure, treat comorbidities (AF, obesity, ischemia), and add an SGLT2 inhibitor (now shown to reduce HF hospitalization). Unlike HFrEF, most neurohormonal drugs have limited mortality benefit.

  15. What is the initial management of acute decompensated heart failure with pulmonary congestion?

    Remember LMNOP: Loop diuretics (IV furosemide), Morphine (rarely used now), Nitrates (vasodilator to reduce preload/afterload), Oxygen/noninvasive positive-pressure ventilation, and Position (sit upright). Identify and treat the precipitant.

  16. How does BNP/NT-proBNP help in acute dyspnea evaluation?

    Elevated B-type natriuretic peptide (BNP) or NT-proBNP supports a cardiac cause of dyspnea (HF), reflecting ventricular wall stretch. A low value has high negative predictive value to rule out HF. Levels are lower in obesity and higher in renal failure and AF.

  17. Contrast the three main cardiomyopathies (dilated, hypertrophic, restrictive) by ventricular size and dysfunction.

    Dilated: enlarged chambers with systolic dysfunction (low EF). Hypertrophic: thick, non-dilated LV with diastolic dysfunction and possible LVOT obstruction (preserved/high EF). Restrictive: normal-sized, rigid walls with diastolic dysfunction and impaired filling (preserved EF).

  18. What is the inheritance and key pathophysiology of hypertrophic cardiomyopathy (HCM)?

    Autosomal dominant mutation in sarcomere genes (e.g., beta-myosin heavy chain). Asymmetric septal hypertrophy can cause dynamic LV outflow tract obstruction and systolic anterior motion of the mitral valve; it is a leading cause of sudden cardiac death in young athletes.

  19. How does the murmur of hypertrophic obstructive cardiomyopathy change with maneuvers?

    The harsh systolic murmur INCREASES with maneuvers that decrease preload/afterload (Valsalva strain, standing) and DECREASES with increased preload/afterload (squatting, handgrip, passive leg raise). Less LV volume worsens the outflow obstruction.

  20. What is the CHA2DS2-VASc score used for, and what does it count?

    It estimates annual stroke risk in atrial fibrillation to guide anticoagulation. Points: CHF (1), Hypertension (1), Age $\geq 75$ (2), Diabetes (1), prior Stroke/TIA (2), Vascular disease (1), Age 65–74 (1), Sex female (1). Anticoagulate if score $\geq 2$ in men or $\geq 3$ in women.

Show the other 30 Cardiovascular System flashcards
  1. Describe the ECG findings of atrial fibrillation versus atrial flutter.

    Atrial fibrillation: irregularly irregular rhythm with absent P waves and a fibrillatory baseline. Atrial flutter: regular sawtooth flutter waves (atrial rate $\approx 300\,\text{bpm}$) with a regular ventricular response, classically $2{:}1$ conduction giving $\approx 150\,\text{bpm}$.

  2. What are the rate-control and rhythm-control options for atrial fibrillation?

    Rate control: beta-blockers or non-dihydropyridine calcium channel blockers (diltiazem/verapamil); digoxin as adjunct. Rhythm control: electrical/pharmacologic cardioversion (must anticoagulate or exclude thrombus with TEE if onset $>48$ h), antiarrhythmics (amiodarone, flecainide), or catheter ablation.

  3. What is the most common type of paroxysmal supraventricular tachycardia (SVT) and its acute treatment?

    AV nodal reentrant tachycardia (AVNRT)—a regular, narrow-complex tachycardia ~150–250 bpm with no visible P waves. Acute treatment: vagal maneuvers first, then IV adenosine; if unstable, synchronized cardioversion.

  4. What is Wolff-Parkinson-White (WPW) syndrome and why is it dangerous in atrial fibrillation?

    A congenital accessory pathway (bundle of Kent) producing a short PR interval, a delta wave, and a wide QRS. In AF, AV-nodal blockers (adenosine, beta-blockers, CCBs, digoxin) can accelerate conduction down the accessory pathway, risking ventricular fibrillation; use procainamide or cardioversion instead.

  5. How do you distinguish and treat monomorphic ventricular tachycardia in a stable versus unstable patient?

    Monomorphic VT is a regular, wide-complex ($>120\,\text{ms}$) tachycardia. Stable: IV antiarrhythmics (amiodarone, procainamide, or lidocaine). Unstable (hypotension, ischemia, altered mental status): immediate synchronized cardioversion. Pulseless VT is treated like VF.

  6. What is the immediate management of pulseless ventricular tachycardia or ventricular fibrillation?

    Immediate unsynchronized defibrillation plus high-quality CPR. Continue ACLS: epinephrine every 3–5 minutes, and amiodarone (or lidocaine) for refractory shockable rhythms. Identify and treat reversible causes (Hs and Ts).

  7. What is torsades de pointes and how is it treated?

    A polymorphic ventricular tachycardia with a twisting QRS axis occurring in the setting of a prolonged QT interval. Treatment: IV magnesium sulfate, correct electrolytes, stop offending drugs, and use overdrive pacing or isoproterenol for bradycardia-dependent cases; defibrillate if pulseless.

  8. Classify the AV blocks by their ECG features.

    First-degree: PR $>200\,\text{ms}$, all P waves conduct. Mobitz I (Wenckebach): progressive PR lengthening until a dropped beat. Mobitz II: constant PR with sudden dropped QRS (His-Purkinje disease, risk of progression). Third-degree (complete): AV dissociation with independent atrial and ventricular rates.

  9. Which bradyarrhythmias require a permanent pacemaker?

    Symptomatic sinus node dysfunction, Mobitz type II second-degree AV block, high-grade or third-degree (complete) AV block, and symptomatic bradycardia not from reversible causes. Mobitz I and first-degree block usually do not require pacing if asymptomatic.

  10. What is congenital long QT syndrome and the main risk it carries?

    An inherited channelopathy (commonly LQT1, LQT2 potassium-channel and LQT3 sodium-channel mutations) causing prolonged ventricular repolarization. It predisposes to torsades de pointes, syncope, and sudden cardiac death. Beta-blockers are first-line; avoid QT-prolonging drugs.

  11. How is the QT interval corrected for heart rate (Bazett's formula)?

    $$QT_c = \frac{QT}{\sqrt{RR}}$$ where QT and RR are in seconds. A $QT_c > 450\,\text{ms}$ in men or $> 460\text{–}470\,\text{ms}$ in women is prolonged; $QT_c > 500\,\text{ms}$ markedly increases torsades risk.

  12. Name two inherited channelopathies besides long QT syndrome and a hallmark feature of each.

    Brugada syndrome: sodium-channel (SCN5A) mutation with coved ST elevation in $V_1\text{–}V_2$ and risk of VF/sudden death, classically during sleep/fever. Catecholaminergic polymorphic VT (CPVT): ryanodine receptor mutation causing exercise/emotion-induced bidirectional VT.

  13. Describe the murmur and key features of aortic stenosis.

    A harsh crescendo-decrescendo (diamond-shaped) systolic ejection murmur at the right upper sternal border radiating to the carotids, with a delayed/weak carotid upstroke (pulsus parvus et tardus). Classic triad: angina, syncope, and exertional dyspnea (heart failure).

  14. What defines severe aortic stenosis hemodynamically, and what is the definitive treatment?

    Severe AS: aortic valve area $< 1.0\,\text{cm}^2$, mean gradient $\geq 40\,\text{mmHg}$, or peak jet velocity $\geq 4\,\text{m/s}$. Definitive treatment of symptomatic severe AS is valve replacement (surgical AVR or TAVR); medical therapy does not change the natural history.

  15. Describe the murmur of chronic aortic regurgitation and its peripheral signs.

    An early decrescendo diastolic blowing murmur at the left sternal border, best heard sitting forward in expiration, with a wide pulse pressure. Peripheral signs include water-hammer (Corrigan) pulse, head bobbing (de Musset), and Quincke pulses; treat with afterload reduction and surgery for symptoms/LV dysfunction.

  16. Describe the murmur and most common cause of mitral stenosis.

    A low-pitched mid-diastolic rumble with an opening snap at the apex, best heard in left lateral decubitus; a loud S1 is typical. The most common cause worldwide is rheumatic heart disease. It can cause left atrial enlargement, atrial fibrillation, and pulmonary hypertension.

  17. Contrast the murmurs of acute versus chronic mitral regurgitation.

    Chronic MR: holosystolic murmur at the apex radiating to the axilla, often well tolerated due to LA compliance. Acute MR (e.g., papillary muscle rupture, endocarditis): early/decrescendo systolic murmur with abrupt pulmonary edema and cardiogenic shock requiring urgent surgery.

  18. What are the Duke criteria categories used to diagnose infective endocarditis?

    Diagnosis requires combinations of major and minor criteria. Major: positive blood cultures with typical organisms, and echocardiographic evidence of endocardial involvement (vegetation, abscess, new valve regurgitation). Minor: predisposing condition, fever $\geq 38^\circ\text{C}$, vascular phenomena, immunologic phenomena, and suggestive microbiology.

  19. Which organisms most commonly cause infective endocarditis in different settings?

    Staphylococcus aureus: most common overall and in acute IE and IV drug users (often tricuspid). Viridans streptococci: subacute IE on previously damaged native valves. Staphylococcus epidermidis: prosthetic valves. Enterococci: post-GU/GI procedures; HACEK organisms cause culture-negative cases.

  20. List the classic peripheral stigmata of infective endocarditis.

    Janeway lesions (painless palms/soles, septic emboli), Osler nodes (painful pulp of fingers, immune complexes), Roth spots (retinal hemorrhages with pale centers), splinter hemorrhages, and petechiae. New murmur, fever, and embolic phenomena complete the picture.

  21. What are the Jones criteria for diagnosing acute rheumatic fever?

    Following group A streptococcal pharyngitis: diagnosis needs 2 major or 1 major + 2 minor criteria plus evidence of prior strep infection. Major (JONES): Joints (migratory polyarthritis), carditis (O = heart), Nodules (subcutaneous), Erythema marginatum, Sydenham chorea. Minor: fever, arthralgia, elevated ESR/CRP, prolonged PR.

  22. Which valve is most affected by rheumatic heart disease and what is the prevention?

    The mitral valve is most commonly affected (mitral stenosis/regurgitation), followed by the aortic valve. Prevention is prompt treatment of streptococcal pharyngitis with penicillin and long-term secondary antibiotic prophylaxis to prevent recurrent rheumatic fever.

  23. How is hypertension classified by the ACC/AHA 2017 guideline?

    Normal: $<120/<80$. Elevated: $120\text{–}129/<80$. Stage 1: $130\text{–}139$ or $80\text{–}89$. Stage 2: $\geq 140$ or $\geq 90\,\text{mmHg}$. Diagnosis requires confirmation on $\geq 2$ readings on $\geq 2$ occasions.

  24. What distinguishes essential (primary) from secondary hypertension?

    Essential hypertension (~90–95% of cases) has no single identifiable cause and is multifactorial (genetics, sodium, obesity, age). Secondary hypertension has an identifiable cause and is suggested by young age, abrupt onset, severe/resistant HTN, or specific clues (e.g., hypokalemia, abdominal bruit).

  25. List common causes of secondary hypertension and a clue for each.

    Primary hyperaldosteronism (hypokalemia, metabolic alkalosis), renal artery stenosis (abdominal bruit, rise in creatinine after ACEi), pheochromocytoma (episodic headache/palpitations/sweating), Cushing syndrome, obstructive sleep apnea, hypo/hyperthyroidism, and coarctation of the aorta (arm-leg BP gradient).

  26. What are the first-line antihypertensive drug classes for essential hypertension?

    Thiazide diuretics, ACE inhibitors, ARBs, and dihydropyridine calcium channel blockers. In Black patients without HF/CKD, thiazides or CCBs are preferred initially; ACEi/ARB are favored with diabetes, CKD, or HFrEF.

  27. Distinguish a hypertensive urgency from a hypertensive emergency.

    Both involve severely elevated BP (often $>180/120\,\text{mmHg}$). Emergency: presence of acute target-organ damage (encephalopathy, stroke, MI, aortic dissection, pulmonary edema, AKI, eclampsia)—requires IV agents with controlled BP lowering. Urgency: no acute organ damage—lower BP gradually with oral agents.

  28. What is the cardiac output equation and how does it relate to blood pressure?

    $$CO = HR \times SV$$ and mean arterial pressure $$MAP = CO \times SVR.$$ Blood pressure is therefore the product of cardiac output and systemic vascular resistance, which is why antihypertensives target heart rate, contractility, volume, or vascular tone.

  29. How is the ejection fraction calculated and what is the normal range?

    $$EF = \frac{SV}{EDV} \times 100\% = \frac{EDV - ESV}{EDV} \times 100\%$$ where EDV is end-diastolic and ESV is end-systolic volume. Normal LVEF is approximately $55\text{–}70\%$; $\leq 40\%$ defines reduced EF heart failure.

  30. What is restrictive cardiomyopathy and a classic systemic cause?

    A non-dilated, rigid ventricle with impaired diastolic filling and preserved systolic function, producing right-sided heart failure with elevated filling pressures. A classic cause is cardiac amyloidosis (also hemochromatosis, sarcoidosis, endomyocardial fibrosis); it must be distinguished from constrictive pericarditis.

Physician Assistant National Certifying Examination (PANCE) Cardiovascular System FAQ

What is in the Physician Assistant National Certifying Examination (PANCE) Cardiovascular System syllabus?

Physician Assistant National Certifying Examination (PANCE) Cardiovascular System is split into 5 chapters: Coronary Heart Disease and Acute Coronary Syndromes, Heart Failure and Cardiomyopathies, Arrhythmias and Conduction Disorders, Valvular and Structural Heart Disease and Vascular Disease and Hypertension. Together they contain 22 topics and 29 sub-topics.

How many chapters are in Physician Assistant National Certifying Examination (PANCE) Cardiovascular System?

5 chapters, containing 22 topics and 29 sub-topics. The largest chapter is Arrhythmias and Conduction Disorders, with 5 topics.

Are there flashcards for Physician Assistant National Certifying Examination (PANCE) Cardiovascular System?

Yes — a 50-card Cardiovascular System deck, printed in full in the flashcards section of this page and available in the Examius app with spaced repetition. The free plan covers one exam of your choice, including its flashcards; Examius Pro, a one-time purchase, unlocks every other exam and deck.